Home › Compare › APLIF vs EQR

APLIF vs EQR: Dividend Comparison 2026

APLIF yields 18181.82% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 APLIF wins by $20382968138483965952.00M in total portfolio value
10 years
APLIF
APLIF
● Live price
18181.82%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20382968138483965952.00M
Annual income
$20,164,798,479,641,134,000,000,000.00
Full APLIF calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — APLIF vs EQR

📍 APLIF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAPLIFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, APLIF + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
APLIF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

APLIF
Annual income on $10K today (after 15% tax)
$1,545,454.55/yr
After 10yr DRIP, annual income (after tax)
$17,140,078,707,694,964,000,000,000.00/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, APLIF beats the other by $17,140,078,707,694,964,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of APLIF + EQR for your $10,000?

APLIF: 50%EQR: 50%
100% EQR50/50100% APLIF
Portfolio after 10yr
$10191484069241982976.00M
Annual income
$10,082,399,239,820,567,000,000,000.00/yr
Blended yield
98.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

APLIF
No analyst data
Altman Z
-234.9
Piotroski
4/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

APLIF buys
0
EQR buys
0
No recent congressional trades found for APLIF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAPLIFEQR
Forward yield18181.82% ✓4.73%
Annual dividend / share$2.00$2.77 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$20382968138483965952.00M ✓$40.5K
Annual income after 10y$20,164,798,479,641,134,000,000,000.00 ✓$3,819.61
Total dividends collected$20368560651224936448.00M ✓$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: APLIF vs EQR ($10,000, DRIP)

YearAPLIF PortfolioAPLIF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$1,828,882$1,818,181.82$11,248$547.57+$1.82M → APLIF
2$312,726,966$310,770,062.56$12,701$666.53+$312.71M → APLIF
3$49,997,862,140$49,663,244,286.24$14,405$814.59+$49997.85M → APLIF
4$7,474,070,205,933$7,420,572,493,443.65$16,413$999.84+$7474070.19M → APLIF
5$1,044,712,232,322,833$1,036,714,977,202,484.10$18,795$1,232.92+$1044712232.30M → APLIF
6$136,547,911,758,351,100$135,430,069,669,765,680.00$21,639$1,527.95+$136547911758.33M → APLIF
7$16,689,313,388,956,088,000$16,543,207,123,374,653,000.00$25,057$1,903.80+$16689313388956.06M → APLIF
8$1,907,542,220,817,720,100,000$1,889,684,655,491,537,200,000.00$29,197$2,385.87+$1907542220817720.25M → APLIF
9$203,896,877,423,206,970,000,000$201,855,807,246,932,000,000,000.00$34,250$3,008.70+$203896877423206976.00M → APLIF
10$20,382,968,138,483,967,000,000,000$20,164,798,479,641,134,000,000,000.00$40,467$3,819.61+$20382968138483965952.00M → APLIF

APLIF vs EQR: Complete Analysis 2026

APLIF — Stock

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.

Full APLIF Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this APLIF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

APLIF vs SCHDAPLIF vs JEPIAPLIF vs OAPLIF vs KOAPLIF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.